Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 14, 2012

View Archived Issues

Osteros Biomedica prepares for proof-of-concept MBC-11 study

Multiple studies confirm D-type cyclins as therapeutic targets in cancer

Adaptimmune presents gene-engineered autologous T cells for multiple myeloma

Immunomedics develops antibodies with potential in the therapeutic intervention of lymphoma

Gilead Sciences patents novel sodium channel blockers

French and U.S. researchers present novel Mdm2 inhibitors for cancer

Janssen submits NDA for canagliflozin/metformin combination

4SC reports interim data from phase I/II trial of resminostat

Milestone reached in DuoBody platform collaboration

Method devised to detect biomarker of idiopathic pulmonary fibrosis

Lamazym advances to phase III alpha-mannosidosis trial

FDA approves supplemental NDA for Rescula

Kyowa Hakko Kirin begins pivotal phase III mogamulizumab study in CTCL

BrainStorm Cell Therapeutics receives grant from Israel's Office of the Chief Scientist

Amgen set to acquire deCODE Genetics

FDA accepts for review NDA for vortioxetine

NIH-sponsored trial of AstraZeneca's TB candidate commences in South Africa

Safety of antimalarial tafenoquine evaluated in phase I study

Japanese scientists present novel agents for Fabry's disease

Matrivax Research & Development Corp. patents new pneumococcal vaccines

New orexin receptor antagonists prepared by Taisho Pharmaceutical

Bayer submits MAA to EMA for prostate cancer treatment

U.S. researchers synthesize novel autophagy inhibitors

AstraZeneca reports on OSKIRA-4 phase IIb fostamatinib study

ISIS-TTRRx receives fast track designation from FDA

Insero Health completes phase Ib study of INS-001

FDA accepts for review macitentan NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...